ORIC - ORIC Pharmaceuticals Inc Stock Price, Fair Value and News

$10.99+0.34 (+3.19%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ORIC Price Action

Last 7 days

-7.0%

Last 30 days

-13.4%

Last 90 days

2.0%

Trailing 12 Months

14.5%

ORIC RSI Chart

ORIC Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-7.91

Price/Sales (Trailing)

19.8K

Price/Free Cashflow

-9.13

ORIC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ORIC Fundamentals

ORIC Revenue

Revenue (TTM)

60.0K

ORIC Earnings

Earnings (TTM)

-135.3M

Earnings Growth (Yr)

5.73%

Earnings Growth (Qtr)

10.36%

ORIC Profitability

Return on Equity

-33.24%

Return on Assets

-31.37%

Free Cashflow Yield

-10.95%

ORIC Investor Care

Shares Dilution (1Y)

38.01%

Diluted EPS (TTM)

-1.73

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	60.0K	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

CEO	Dr. Jacob M. Chacko M.B.A., M.D.
WEBSITE	oricpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	89

ORIC Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ORIC Pharmaceuticals Inc? What does ORIC stand for in stocks?

ORIC is the stock ticker symbol of ORIC Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ORIC Pharmaceuticals Inc (ORIC)?

As of Wed Dec 03 2025, market cap of ORIC Pharmaceuticals Inc is 1.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORIC stock?

You can check ORIC's fair value in chart for subscribers.

Is ORIC Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ORIC is over valued or under valued. Whether ORIC Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ORIC Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORIC.

What is ORIC Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ORIC's PE ratio (Price to Earnings) is -7.91 and Price to Sales (PS) ratio is 19.8 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORIC PE ratio will change depending on the future growth rate expectations of investors.